Industry-friendly reimbursement vital in Japan
This article was originally published in Clinica
The availability of breakthrough medical technologies in Japan - the C2 category of product - could be improved by adopting reimbursement policies that are more responsive to innovation, industry believes. Industry and patients are currently impeded by the fact that C2 products are ineligible for reimbursement for at least two years after receipt of regulatory approval.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.